CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine

CurifyLabs, a health technology company specializing in personalized medicine, has successfully closed a $14 million Series A funding round. The financing, announced on July 6, 2026, was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. The funds will be allocated towards enhancing U.S. operations, fortifying supply chain infrastructure, improving customer support, and accelerating product innovation.

Founded in 2021, CurifyLabs has developed a Compounding System Solution (CSS) that integrates proprietary software, GMP-manufactured excipients, and advanced 3D printing technology to streamline the preparation of personalized medications. This technology enables pharmacies to produce tailored doses and dosage forms with greater precision and speed compared to traditional manual compounding methods. Currently, CurifyLabs serves compounding pharmacies across 21 U.S. states and Europe, facilitating the compounding and dispensing of thousands of doses daily.

The strategic rationale behind the investment from Sandwater, HealthCap, and Tesi lies in the growing demand for personalized medicine, which is increasingly recognized as a vital frontier in healthcare. The funding will allow CurifyLabs to expand its operational capabilities in the U.S. market, ensuring that its pharmacy partners have timely access to the necessary resources. The investment will also bolster customer support and research and development efforts, which are critical as the company seeks to enhance its product offerings, including its latest innovation, the PharmaPrinter Aurum.

The health technology sector is experiencing robust growth, driven by advancements in personalized medicine and increasing patient demand for tailored therapies. As CurifyLabs continues to scale its operations, the company is well-positioned to capitalize on this trend. The backing from prominent investors underscores the confidence in CurifyLabs' ability to deliver innovative solutions that combine clinical rigor with operational efficiency, thereby transforming the landscape of personalized medication.

In conclusion, the successful fundraising round not only strengthens CurifyLabs' position within the health technology sector but also reflects broader market dynamics favoring innovative healthcare solutions. As personalized medicine continues to gain traction, companies like CurifyLabs that leverage technology to enhance patient outcomes are likely to play a pivotal role in shaping the future of healthcare delivery. The investment from Sandwater, HealthCap, and Tesi signals a commitment to supporting the growth of such transformative companies in the evolving health technology landscape.